Further to the Government’s announcement to legalize the sale of recreational cannabis on October 17, on June 27, Health Canada announced two key developments on the cannabis file that would be of interest to us, our clients and potential partners:
Health Canada issued a notice of intent to add phytocannabinoids including CBD and THC to the Human and Veterinary Prescription Drug List (PDL) effective on October 17. Ingredients on the PDL would be required to be sold as a prescription drugs, as such, over-the-counter health products such as NHPs, would not be permitted to contain phytocannabinoids. Derivatives of cannabis under the Industrial Hemp Regulations or referenced under Schedule 2 of the Cannabis Act and contain less than 10ppm THC are exempt from inclusion on the PDL and will remain unaffected.
Further evidence will need to be submitted to Health Canada to change the prescription status of phytocannabinoids, until which time they will remain on the PDL.
Our team and other industry professionals have expressed concerns to Health Canada. This serves as a step back from the current medical access, and appears to be hardened to cross-border trade considerations as well as 18 years of court decisions supporting fair and reasonable access to cannabis products for medical use.
On June 27, Health Canada announced that the Cannabis Regulations, which will outline rules for the cultivation, testing, sales, packaging and labelling of cannabis products and support the coming into force of the Cannabis Act, will be published in Canada Gazette, Part II on July 11. The regulations will come into force on October 17 at which time cannabis will be regulated under the Cannabis Act and no longer under the Controlled Drugs and Substances Act.
Our team has been making note of the growing interest in cannabis products and resulting confusion surrounding the regulatory framework for cannabis-containing health products in the Canadian market. That’s why we have a special team of experts maintaining attention to the topic, so that you can get the latest information available.
Would you like to chat with us directly about this and how will affect you and your product? No worries! Email us at email@example.com or call us at 204.254.2234 and get in touch, we always have time for you.